Indoco Remedies logo

Indoco Remedies financials: balance sheet, profit and loss, cash flow

NSE: INDOCOBSE: 532612Pharmaceuticals & BiotechnologySmall Cap

Indoco Remedies Limited · Face value ₹2 · Listed Jan 2005
Last close ₹213.75down ₹6.90 (3.13%)BSE ₹214.05

Share price at the NSE close on 28 Oct 2026. Previous close ₹220.65.

28 Oct: open ₹219.20, high ₹220.40, low ₹211.25

52-week range of traded prices to 28 Oct 2026
₹162.19Low, 30 Mar 2026₹288.00High, 6 Nov 2025
Market cap
₹1,973 Cr1,173rd largest listed
P/E
61.77
P/E without one-offs
Lossover the last 12 months
P/B
1.93
Dividend yield
0.09%
ROE
3.2%
ROE without one-offs
−10.0%
ROCE
1.8%
Debt to equity
0.96
Volume, NSE
1,82,27841.5% delivered

Indoco Remedies' financial statements for the 10 years to Mar 2026, consolidated: the company and its subsidiaries together, with the half year to Sep 2026 after them.

10 years at a glance

₹ crore, years to March.Indoco Remedies annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
  • Loss
1,09777Mar 171,04541Mar 18968−2.9Mar 191,10724203Mar 201,24293213Mar 211,541155244Mar 221,669142333Mar 231,81797672Mar 241,665−78994Mar 251,845−991,036Mar 26
Peak revenue ₹1,845 Cr, year to Mar 2026; lowest ₹968 Cr, year to Mar 2019A loss in 3 of the 10 years shown

Operating and net margin, per cent

  • Operating margin
  • Net margin
21.2%−5.3%14.3%12.9%7.9%11.1%18.1%21.2%17.1%13.4%6.0%7.7%7.0%3.9%−0.3%2.2%7.5%10.0%8.5%5.3%−4.7%−5.3%Mar 17Mar 19Mar 21Mar 23Mar 25Mar 26

From Apr 2019 leases sit on the balance sheet: rent is charged as depreciation and interest instead, so operating profit and total assets step up with nothing about the business having changed. Borrowings here leave lease liabilities out. Lease payments were 5.3% of operating profit in the first full year.

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue1,845
  2. Materials and goods−542
  3. Employee costs−426
  4. Other expenses−736
  5. Operating profit142
  6. Depreciation−126
  7. Other income+3.3
  8. One-off items−2.9
  9. Finance costs−122
  10. Profit before tax−107
  11. Tax+7.8
  12. Net profit−99

What the company owns

  • Plant, investments and other assets₹1,666 Cr
  • Receivables₹489 Cr
  • Inventory₹405 Cr
  • Cash and bank₹33 Cr

What pays for it: net worth and liabilities

  • Borrowings₹1,036 Cr
  • Net worth₹932 Cr
  • Other liabilities₹317 Cr
  • Owed to suppliers₹309 Cr

Profit and loss

Consolidated, ₹ crore, years to March. The last column is the twelve months to Sep 2026, the latest four quarters added.Indoco Remedies quarterly results

₹ croreMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Filed 17 MayMar 2023Mar 2024Mar 2025Filed 22 MayMar 2026Sep 2026Twelve monthsFiled 27 Oct
Revenue from operations1,0971,0459681,1071,2421,5411,6691,8171,6651,8451,909
9409108929831,0171,2131,3831,5731,5661,7041,740
Materials and goods bought383351320330354457521559498542599
Employee costs–––257274294323362394426422
Other expenses–––396389463539652673736719
Operating profit before depreciation1561357712322432728624499142169
Operating margin14.3%12.9%7.9%11.1%18.1%21.2%17.1%13.4%6.0%7.7%8.8%
Materials, % of revenue–––29.9%28.5%29.6%31.2%30.8%29.9%29.4%31.4%
Employee costs, % of revenue–––23.2%22.1%19.1%19.3%19.9%23.7%23.1%22.1%
Other expenses, % of revenue–––35.8%31.3%30.0%32.3%35.9%40.4%39.9%37.7%
Depreciation and amortisation6368727173797192114126133
Operating profit after depreciation9367552151248215152−151535
Other income456232210535
Finance costs62421262214253866122127
Profit before one-off items and tax9148−929132237193124−75−104−86
One-off items0000000121−3132
Profit before tax9148−929132237193136−74−10746
147−64398251394−814
7741−3249315514297−78−9932
Other comprehensive income–––−2−1−510−41311
Total comprehensive income–––229214914497−82−8642
Net margin7.0%3.9%−0.3%2.2%7.5%10.0%8.5%5.3%−4.7%−5.3%1.7%
Materials, employee costs and other expenses are shown for the years they add up to operating expenses; for the years to Mar 2017, Mar 2018 and Mar 2019 they do not, so they are left blank.

Balance sheet

Consolidated, ₹ crore, at 31 March. The last column is the half year to Sep 2026, after the latest full year: the balance sheet at its end.

₹ croreMar 2020Mar 2021Mar 2022Filed 17 MayMar 2023Mar 2024Mar 2025Filed 22 MayMar 2026Sep 2026Half yearFiled 27 Oct
6807699051,0281,1111,0189321,016
6807699051,0281,1101,0229391,022
Share capital1818181818181818
Reserves6617518861,0101,0911,0049211,003
Belonging to outside owners of subsidiaries––––1−4−7−6
2032132443336729941,036976
4594074254256128081,053972
133139157205422604609625
Total assets1,2721,3151,4861,6582,1452,4302,5932,613
7086937128501,1901,4291,4001,387
5636237748089551,0011,1931,226
Net debt1651992243196409761,003924
Borrowings are counted again inside the liabilities due within a year and after a year. Plant in use and plant being built are given for full years only. No balance sheet is on record for the years to Mar 2017, Mar 2018 and Mar 2019, so its lines and the ratios worked from it are blank there.

Cash flow

Consolidated, ₹ crore, years to March. The last column is the half year to Sep 2026, after the latest full year: the cash flow over its six months.

₹ croreMar 2021Mar 2022Filed 17 MayMar 2023Mar 2024Mar 2025Filed 22 MayMar 2026Sep 2026Half year
8217417915795192185
102215240186112198175
−140−109−73−87356−58
Receivables−40−59−79−6451−137−55
Inventories−30−73−15−27−66149
Payables−5121−93055105−28
Other working capital−19130−26−367417
Tax paid−20−41−62−29−17−69
Capital spending7712520742735614860
Free cash flow549−28−271−26145124
−67−121−208−434−339−102−49
−30−4423280241−77−126
Dividends paid31421211422
Shares bought back0000000
Shares issued0001210
Net change in cash−148−73−3149
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019 and Mar 2020.

Per share

Consolidated, ₹ per share, years to March.Indoco Remedies dividend history

₹ per shareMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Filed 17 MayMar 2023Mar 2024Mar 2025Filed 22 MayMar 2026
Earnings per share₹8.36₹4.47−₹0.31₹2.62₹10.10₹16.80₹15.44₹10.53–−₹10.70
Diluted earnings per share₹8.36₹4.47−₹0.31₹2.62₹10.10₹16.80₹15.42₹10.51–−₹10.69
Dividend per share₹1.60₹1.00₹0.30₹0.30₹1.50₹2.25₹2.25₹1.50₹0.20₹0.20
Book value per share–––₹73.75₹83.45₹98.17₹111.58₹120.38₹110.79₹101.76
Dividend payout19.1%22.4%–11.5%14.9%13.4%14.6%14.0%––
Shareholder yield––––0.1%0.4%0.7%0.7%0.6%0.0%
Market cap at the year end (₹ crore)2,2961,9551,8641,9392,6503,4752,9973,0292,1471,513
Earnings per share is left blank for the year to Mar 2025: the earnings per share stated has the opposite sign to the profit stated beside it, so it is not shown.

Ratios

Consolidated, years to March.Indoco Remedies PE ratio and valuation

RatioMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Filed 17 MayMar 2023Mar 2024Mar 2025Filed 22 MayMar 2026
Revenue growth9.3%−4.7%−7.4%14.3%12.2%24.1%8.3%8.9%−8.4%10.8%
Operating profit growth−9.2%−13.8%−43.2%60.7%82.0%46.0%−12.6%−14.6%−59.4%42.9%
Net profit growth−7.1%−46.6%––285.8%66.4%−8.1%−31.8%––
Earnings per share growth–−46.5%––285.5%66.3%−8.1%−31.8%––
–––3.5%12.8%18.5%14.7%9.2%−6.9%−9.7%
––––9.3 pts5.7 pts−3.8 pts−5.5 pts−16.1 pts−2.8 pts
From the net margin––––8.7 pts4.4 pts−2.8 pts−5.4 pts−16.7 pts−1.1 pts
From asset turnover––––1.3 pts2.5 pts−0.6 pts−0.9 pts1.8 pts−0.1 pts
From borrowing––––−0.6 pts−1.2 pts−0.4 pts0.8 pts−1.2 pts−1.6 pts
Return on capital employed–––5.9%15.4%21.6%15.8%8.6%−0.7%0.8%
Cash conversion––––88.4%112.3%125.7%161.5%––
Interest cover15.02.90.22.06.817.68.64.0–0.1
Debt to equity–––0.300.280.270.320.610.981.11
Receivable days–––69697077827797
Inventory days–––230245248228230307273
Payable days–––18311710786100152208
Cash conversion cycle, days–––117197212219212232162
Working capital days–––5793113119124138124
Asset turnover–––0.870.961.101.060.960.730.73
Assets per rupee of net worth–––1.871.791.671.631.782.152.56
Sales per rupee of plant–––2.042.352.902.732.311.961.90
Capital spending to depreciation––––1.051.592.944.653.131.17
Plant being built, % of plant in use–––1.4%4.8%9.9%9.0%13.1%32.5%2.9%
Interest cover is left blank for the year to Mar 2025: operating profit after depreciation is a loss, and a loss covers no interest bill. No balance sheet is on record for the years to Mar 2017, Mar 2018 and Mar 2019, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
−3.8%
Cash from operations against operating profit
135.6%
Measure10 years5 years3 years
Revenue growth, yearly rate6.3%8.2%3.4%
Return on equity, average–5.2%−2.5%
Return on capital employed, average–9.2%2.9%
Operating margin, average13.0%13.1%9.0%
Net margin, average3.4%2.8%−1.6%
Asset turnover, average–0.920.81
Cash conversion cycle, days, average–207202
Interest cover, average6.47.62.1
Debt to equity, average–0.660.90

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations797444192
Cash from investing−1,204−875−102
Cash from financing424445−77
Capital spending1,264931148
Dividends paid71372
Shares bought back000
Shares issued for cash441
Borrowings raised854662147
Borrowings repaid37123689

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9–––––85434
Altman Z-scorePublished threshold 1.81–––3.805.246.305.423.782.261.84
Beneish M-scorePublished threshold −1.78––––−2.33−2.28−2.33−2.47−2.95−2.83
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets––––5.997.3110.9219.687.27−7.54
Cash from operations to profit, 3 yearsPublished threshold 0.7 times––––––1.111.292.67–
Receivables growth less revenue growthOur threshold 0 percentage points––––−0.933.029.776.84−4.8627.97
Inventory growth less cost-of-goods growthOur threshold 0 percentage points––––7.011.56−9.141.0329.69−12.12
Other current assets growth less revenue growthOur threshold 5 per cent of revenue––––2.400.61−1.762.542.812.82
Assets under construction, years of additionsOur threshold 2 years of additions––––0.420.640.370.381.580.11
Effective tax ratePublished threshold 17.16 per cent15.2614.96–15.6129.5134.5626.2228.56––
Tax charged less tax paid, % of profitOur threshold 10 percentage points–––––17.20−5.766.85––
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
30 Sep 2026ICRA LimitedUnallocated limits-Unallocated limits[ICRA]A /[ICRA]A2+Review, Re-affirmNegative80
30 Sep 2026ICRA LimitedNon-fund based-Others[ICRA]A2+Review, Re-affirm20.25
30 Sep 2026ICRA LimitedFund-based-Cash credit[ICRA]AReview, Re-affirmNegative94.40
30 Sep 2026ICRA LimitedFund-based-Others[ICRA]A2+Review, Re-affirm335
30 Sep 2026ICRA LimitedFund-based-Term loan[ICRA]AReview, Re-affirmNegative400
30 Sep 2026ICRA LimitedFund-based-Others[ICRA]A /[ICRA]A2+Review, Re-affirmNegative90
24 Sep 2025ICRA LimitedUnallocated-Unallocated[ICRA]A /[ICRA]A2+Review, Re-affirmNegative80
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.